Abstract:Abstract Background Glioblastoma is the most common primary brain tumor and remains uniformly fatal, highlighting the dire need for developing effective therapeutics. Significant intra- and inter-tumor heterogeneity and inadequate delivery of therapeutics across blood–brain barrier continue to be significant impediments towards developing therapies which can significantly enhance survival. We hypothesize that microRNAs have the potential to serve as effective therapeutics for glioblastoma as they modulate the activity of multiple signaling pathways, and hence can counteract heterogeneity if successfully delivered. Methods Using a computational approach, we identified microRNA-34a as a microRNA that maximally reduces the activation status of the three core signaling networks (the receptor tyrosine kinase, p53 and Rb networks) that have been found to be deregulated in most glioblastoma tumors. Glioblastoma cultures were transfected with microRNA-34a or control microRNA to assess biological function and therapeutic potential in vitro. Nanocells were derived from genetically modified bacteria and loaded with microRNA-34a for intravenous administration to orthotopic patient-derived glioblastoma xenografts in mice. Results Overexpression of microRNA-34a strongly reduced the activation status of the three core signaling networks. microRNA-34a transfection also inhibited the survival of multiple established glioblastoma cell lines, as well as primary patient-derived xenograft cultures representing the proneural, mesenchymal and classical subtypes. Transfection of microRNA-34a enhanced temozolomide (TMZ) response in in vitro cultures of glioblastoma cells with primary TMZ sensitivity, primary TMZ resistance and acquired TMZ resistance. Mechanistically, microRNA-34a downregulated multiple therapeutic resistance genes which are associated with worse survival in glioblastoma patients and are enriched in specific tumor spatial compartments. Importantly, intravenous administration of nanocells carrying miR-34a and targeted to epidermal growth factor receptor (EGFR) strongly enhanced TMZ sensitivity in an orthotopic patient-derived xenograft mouse model of glioblastoma. Conclusions Targeted bacterially-derived nanocells are an effective vehicle for the delivery of microRNA-34a to glioblastoma tumors. microRNA-34a inhibits survival and strongly sensitizes a wide range of glioblastoma cell cultures to TMZ, suggesting that combination therapy of TMZ with microRNA-34a loaded nanocells may serve as a novel therapeutic approach for the treatment of glioblastoma tumors.

MiR-181b Suppresses Proliferation of and Reduces Chemoresistance to Temozolomide in U87 Glioma Stem Cells

miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.

MiR-181b-5p modulates chemosensitivity of glioma cells to temozolomide by targeting Bcl-2

Dnmt1 Mediates Chemosensitivity By Reducing Methylation Of Mirna-20a Promoter In Glioma Cells

miR-19b-3p inhibits glioma progression via interacting with lncRNA HAGLR

[Down-Regulation of Lncrna TTTY15 Targeting Mir-4500 to Inhibit the Biological Characteristics of A172 Glioma Cells].

miR-23b-5p promotes the chemosensitivity of temozolomide via negatively regulating TLR4 in glioma

Mir-138-5p Suppresses Glioblastoma Cell Viability and Leads to Cell Cycle Arrest by Targeting Cyclin D3.

Long Non-Coding RNA HOTAIRM1 Promotes Proliferation and Inhibits Apoptosis of Glioma Cells by Regulating the Mir-873-5p/zeb2 Axis

Suppressive effect of miR-137 on proliferation and apoptosis of U87 glioma cells in vitro

MicroRNA-16 Inhibits Glioma Cell Growth and Invasion Through Suppression of BCL2 and the Nuclear Factor-Κb1/mmp9 Signaling Pathway.

MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1

miR-9-5p Mediates ABCC1 to Elevate the Sensitivity of Glioma Cells to Temozolomide

MicroRNA-221 Targeting PI3-K/Akt Signaling Axis Induces Cell Proliferation and BCNU Resistance in Human Glioblastoma.

Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma

MicroRNA-206 Inhibited the Progression of Glioblastoma Through BCL-2.

MicroRNA-378 Enhances Inhibitory Effect of Curcumin on Glioblastoma

miR-4530 inhibits the malignant biological behaviors of human glioma cells by directly targeting RTEL1

MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma.

MicroRNA-509-3p Inhibits Cell Proliferation and Invasion Via Downregulation of X-linked Inhibitor of Apoptosis in Glioma.

miR-152-5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7